Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Glioblastoma, a deadly brain cancer that has grabbed headlines for claiming the lives of Sens. Edward Kennedy and John McCain, could be "tricked" into sparing more of its victims.
Merck, the vibrant science and technology company, recognized three graduate students who have demonstrated innovation in life science at an awards ceremony at the company’s global headquarters in Darmstadt, Germany recently.
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.
Scientists at the Virginia Tech Carilion Research Institute have solved a 125-year-old mystery of the brain, and, in the process, uncovered a potential treatment for acquired epilepsy.
A new study by UT Health San Antonio researchers found that a molecule thousands of times smaller than a gene is able to kill medulloblastoma, the most common childhood brain cancer.
Glioblastoma is a serious and incurable brain cancer. Patients receiving this diagnosis typically have 11-20 months to live. One of the main difficulties in treating this cancer is that its cells quickly build up a resistance to chemotherapy.
A clinical trial has shown that a special chemical makes brain tumours glow pink. This can help neurosurgeons operate easily on them and remove them completely and safely say the researchers. The results of this study were presented at the 2018 NCRI Cancer Conference in Glasgow.
Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for stem cell research since 2002, today announced that they have successfully finished printing 3D Brains from brain stem cells for studying neurological disease stages.
A recent study published online in the Journal of Molecular Diagnostics demonstrated that Droplet Digital PCR technology can be used to detect mutations in a region of our DNA that is linked to many cancer types, paving the way for the development of new cancer diagnostics and therapies.
Today, Penn Medicine is announcing the newest Translational Center of Excellence in the Abramson Cancer Center, focused on Glioblastoma Multiforme, the most common and lethal form of brain cancer.
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.
A new study from Helsinki University Hospital, University of Helsinki and the Finnish Cancer Registry shows that survival after glioblastoma has improved since the millennium. The improvement in survival was, however, modest in elderly patients, raising concerns whether current treatment strategies are optimal for this patient group.
A new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of treatment even before changes are identified on scans, according to research led by UCSF Benioff Children’s Hospitals and Children’s National Health System.
A specific protein called TEAD1 is an important regulator of tumor migration in glioblastoma, the most common brain tumor in adults, and deactivating this protein may stop tumor cells from migrating away from the main tumor mass, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 1 in the journal Nature Communications.
Combating glioblastoma remains a major challenge due the complex nature of these tumors, the inability of drugs to penetrate the brain tissue, and lack of correlation between animal models and the human condition.
Zika virus infection is a dreaded one that can lead to severe brain damage in the unborn babies of mothers who get it.
Researchers at The University of Texas Medical Branch at Galveston have successfully harnessed a Zika virus vaccine under development to target and kill the brain cancer known as glioblastoma.
An international team of researchers has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice.
Rush University Medical Center is part of a new clinical trial testing whether an experimental vaccine can help patients' immune systems stop the spread of glioblastoma -- an aggressive form of brain cancer with veryhttps://www.rush.edu/news/press-releases/rush-testing-new-brain-cancer-vaccine few current treatment options.